Theravance Biopharma, Inc. 8-K Filing

Ticker: TBPH · Form: 8-K · Filed: Sep 10, 2024 · CIK: 1583107

Theravance Biopharma, Inc. 8-K Filing Summary
FieldDetail
CompanyTheravance Biopharma, Inc. (TBPH)
Form Type8-K
Filed DateSep 10, 2024
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Theravance Biopharma, Inc. (ticker: TBPH) to the SEC on Sep 10, 2024.

What are the key financial figures in this filing?

Key dollar amounts include: $0.00001 (e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke).

How long is this filing?

Theravance Biopharma, Inc.'s 8-K filing is 2 pages with approximately 541 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-10 06:02:13

Key Financial Figures

  • $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Members of the Theravance Biopharma, Inc. management team will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, and will be conducting one-on-one meetings with analysts and investors during the conference using a slide presentation which is being furnished pursuant to Regulation FD as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Slide deck entitled Investor Presentation September 2024 104 Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERAVANCE BIOPHARMA, INC. Date: September 10, 2024 By: /s/ Aziz Sawaf Aziz Sawaf Senior Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.